Skip to content
Screener

Tango Therapeutics TNGX Other income, net (Note 6)

Other income, net (Note 6) at other companies

Exelixis logo
ExelixisEXEL
$54K+8.0%
Erasca, Inc. logo
Erasca, Inc.ERAS
$22K+129%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$140K-2,700%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$18K-35.7%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$18K+5.9%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.72B+570%
Enterprise value$4.59B+558%
P/S82.9×+53.9×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-221656
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Loss from operations(48,769)(42,530)
Other income:
Interest income2,1771,614
Other income, net1,0791,074
Total other income, net3,2562,688
Loss before income taxes(45,513)(39,842)
Provision for income taxes(1)(34)
Net loss$(45,514)$(39,876)

Item 1. Financial Statements.

FAQ

What is Tango Therapeutics's other income, net (note 6)?
Tango Therapeutics (TNGX) reported other income, net (note 6) of $1.08M in Q1 2026.
How has Tango Therapeutics's other income, net (note 6) changed year-over-year?
Tango Therapeutics's other income, net (note 6) increased by 0.5% year-over-year, from $1.07M to $1.08M.
What is the long-term trend for Tango Therapeutics's other income, net (note 6)?
Over 4 years (2021 to 2025), Tango Therapeutics's other income, net (note 6) has grown at a 101.3% compound annual growth rate (CAGR), from -$248K to $4.07M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Tango Therapeutics's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude